For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Research and development expenses | - | 411* | ||
| General and administrative expenses | - | 455* | ||
| Intangible asset and goodwill impairment expenses | - | 2,420* | ||
| Operating loss | - | -3,286* | ||
| Financial expense (income), net | - | 14* | ||
| Loss before tax expenses | - | -3,272* | ||
| Research and development expenses | 473 | - | ||
| General and administrative expenses | 266 | - | ||
| Operating loss | -739 | - | ||
| Tax expenses | - | 90* | ||
| Financial income, net | 14 | - | ||
| Net loss and comprehensive loss | -725 | -3,362 | ||
| Basic EPS | 0.01 | -0.055 | ||
| Diluted EPS | 0.01 | -0.055 | ||
| Basic Average Shares | 60,729,100 | 60,729,100 | ||
| Diluted Average Shares | 60,729,100 | 60,729,100 | ||
Revium Rx. (RVRC)
Revium Rx. (RVRC)